| 128.75 -7.8 (-5.71%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 166.97  |
1-year : | 177.33 |
| Resists | First : | 142.95 |
Second : | 151.83 |
| Pivot price | 139.49 |
|||
| Supports | First : | 128.61 |
Second : | 107 |
| MAs | MA(5) : | 136.99 |
MA(20) : | 140.01 |
| MA(100) : | 133.96  |
MA(250) : | 107.89 |
|
| MACD | MACD : | -2.3 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 17.8 |
| RSI | RSI(14): 31.4 |
|||
| 52-week | High : | 160.8 | Low : | 73.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PTGX ] has closed below the lower bollinger band by 23.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 17.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 136.73 - 137.39 | 137.39 - 138.05 |
| Low: | 126.72 - 127.52 | 127.52 - 128.32 |
| Close: | 127.27 - 128.54 | 128.54 - 129.79 |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Fri, 16 Oct 2026
Protagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks Research - MarketBeat
Fri, 16 Oct 2026
Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setup - ChartMill
Thu, 15 Oct 2026
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Thu, 15 Oct 2026
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
Thu, 15 Oct 2026
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Wed, 14 Oct 2026
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 5.289e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 7,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 5.988e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 29.3 % |
| Operating Margin | 74.3 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | 10.9 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 492.89 |
| Sales Per Share | 1.8552e+008 |
| EBITDA (p.s.) | 1.8552e+008 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 131 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 15.04 |
| Dividend | 0 |
| Forward Dividend | 9.35e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|